CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls |
| |
| Institution: | 1. Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands;2. Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands;1. Department of Ecology and Evolutionary Biology, Cornell University, Ithaca, New York;2. Department of Animal Science, Cornell University, Ithaca, New York;1. Department of Pathology, University of Washington School of Medicine, Seattle, Washington;5. Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington;2. Department of Endocrinology and Metabolism and Xiamen Diabetes Institute, the First Affiliated Hospital of Xiamen University, Xiamen, China;3. Department of Biostatistics, University of Washington School of Public Health, Seattle, Washington;4. Department of Neurology, the Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, New York;6. Geriatric Research, Education, and Clinical Center, Veterans Affairs of Puget Sound Health Care System, Seattle, Washington;1. Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France;2. CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France;3. GAIA Research Center, Bioanalytical Department, The Goulandris Natural History Museum, Kifissia 14562, Greece;4. National and Kapodistrian University of Athens Medical School, Department of Internal Medicine, 75 Mikras Asias Street, Athens 11527, Greece;5. National and Kapodistrian University of Athens Medical School, Department of Pharmacology, 75 Mikras Asias Street, Athens 11527, Greece;1. Department of Neurology, National Neuroscience Institute, Singapore;2. Parkinson''s Disease and Movement Disorders Centre (NPF International Center of Excellence), National Neuroscience Institute, Singapore;3. Duke-NUS Graduate Medical School, Singapore;1. Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy;2. IRCCS Fondazione Santa Lucia, Rome, Italy;3. Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, Rome, Italy |
| |
| Abstract: | Differential diagnosis between Parkinson's disease (PD) and multiple system atrophy (MSA) is difficult, particularly at early disease stages, but is important for therapeutic management. The protein DJ-1 is implicated in the pathology of PD but little is known about its involvement in MSA. We aimed to determine the diagnostic value of CSF DJ-1 and tau proteins for discriminating PD and MSA. DJ-1 and total tau levels were quantified in the CSF of 43 PD patients, 23 MSA patients and 30 non-neurological controls matched for age and gender. Patients were part of a study with a 3-year prospective design with extended case-review follow-up of up to 9 years, ensuring maximum accuracy of the clinical diagnosis. Our results showed that CSF DJ-1 levels could distinguish MSA from PD with a 78% sensitivity and 78% specificity (AUC = 0.84). The combination of DJ-1 and tau proteins significantly improved this discrimination to 82% sensitivity and 81% specificity to identify MSA from PD (AUC = 0.92). Our results highlight the potential benefits of a combination of DJ-1 and total tau as biomarkers for differential diagnosis of MSA and PD. |
| |
| Keywords: | Parkinson's disease Multiple system atrophy DJ-1 Cerebrospinal fluid Biomarkers |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
